RE:ichor and szls in the newsI wonder if SZLS has reached out to any publications, TV, Radio, anything regarding the FIRST ever LAUNCH of an early detection cancer through Liquid Biopsy.
Today, more than 100,000 patients in the U.S. have benefited from the ColonSentry test.
Our next generation test, Aristotle, uses proven technology to test for ten cancers from a single blood sample. Aristotle has high sensitivity and specificity across multiple cancers. In addition to cancer Aristotle has the ability to test for multiple disease states including Psychiatric Disorders, Heart Disease and Autoimmune Disorders.